Ohtuvayre (Ensifentrine)-How much does a box of Ensifentrine cost in Hong Kong in 2025?

Ohtuvayre (Ensifentrine) is a first-in-class selective dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). The emergence of this new drug brings new hope for the treatment of chronic obstructive pulmonary disease (COPD). On June 26, 2024, the U.S. Food and Drug Administration (FDA) approved Ensifentrine inhaled products for the treatment of COPD in adults. Not only does this approval mean the drug can be used safely and effectively in patients, it also enables it to be delivered directly to the lungs, allowing for better therapeutic results.

In clinical application,Ohtuvayre can significantly improve the patient's respiratory function by inducing the effect of a bronchodilator, while reducing the inflammatory response caused by COPD. This provides a new treatment option for many patients suffering from chronic respiratory diseases, helping them relieve symptoms, improve quality of life, and improve their ability to carry out daily activities.

AlthoughOhtuvayre has been approved and started to be used in the international market, its original version has not yet been launched in China, so the specific price and medical insurance policy of the drug are still unclear. For domestic patients in need, the ways to purchase this drug are relatively limited and can usually only be obtained through relevant overseas channels.

According to current information,The common strength of Ohtuvayre is 3mg/2.5mL (60 doses), and its original version has been sold in some pharmacies. In terms of price, each box sells for about HKD 44,500, which is about more than 40,000 yuan converted into RMB. Please note that prices may fluctuate due to exchange rate changes and other factors. In addition, when considering purchasing, patients should also pay attention to relevant customs policies and medical regulations to ensure legal compliance.

Reference materials:https://go.drugbank.com/drugs/DB16157